The lecture was talking about the way that pharmacology and genomics could be linked together. It was a basic lecture (I'm only in my first year) but the lecturer did mention statin-induced myopathy and the selective action of herceptin only on people who have HER2 (breast cancer). He then went onto drugs being tailored to genetic variants such as in cytochrome P450 enzymes.
What you type sounds very interesting. Engineering cells like that would definitely treat a lot of illnesses that are currently difficult to treat.
Genetic manipulation and matching is a good way forward; I think research is pointing into this direction. As my lecturer called, "pharmacogenomics".
|